A phase IA, two-arm, multicenter, dose-escalation study of oral AEE788 administered either daily or twice weekly in adult patients with advanced colorectal cancer with liver metastases
Latest Information Update: 13 Dec 2005
At a glance
- Drugs AEE 788 (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Adverse reactions
- Sponsors Novartis
- 13 Dec 2005 New trial record.